Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8032628 | 0.93 | SCN8A (0.57) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL7981773 | 0.88 | SCN8A (0.59) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL4239980 | 0.86 | DPP7 (0.59) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL13918962 | 0.83 | BCHE (0.54) | SCN8AMEN1KMT2AKDM4EBCHE | |
| SCHEMBL19288550 | 0.83 | SCN8A (0.57) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL7249965 | 0.83 | TAAR1 (0.62) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL4245054 | 0.83 | SCN8A (0.60) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL4260305 | 0.82 | RHOC (0.53) | SCN8AMEN1KMT2AKDM4EMLYCD | |
| SCHEMBL22579188 | 0.82 | KDM4E (0.63) | SCN8ADPP7MEN1KMT2AKDM4E | |
| SCHEMBL4406202 | 0.82 | SCN8A (0.56) | SCN8ADPP7MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837624-B1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9676736-B2 | 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| EP-2837624-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | disclosed |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087828-A1 | 4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF | OPRK1, HTR3C, HTR3A | SCN8A 916/4885DPP7 652/4885MEN1 1273/4885 |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | SCN8A 1026/4885DPP7 1600/4885MEN1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.